Neuronasal is focused on addressing significant medical challenges, specifically in the treatment of Parkinson's Disease (PD) and Mild Traumatic Brain Injury (mTBI). The company has developed a novel intranasal delivery method for N-acetylcysteine (NAC), an FDA-approved drug, which is designed to effectively transport the medication directly to targeted brain regions. This innovative approach is patent-protected and has demonstrated its potential in a human pilot trial, overcoming the limitations of traditional high intravenous or oral dosing methods that are not suitable for patient use. The company has received a Phase 1 clinical dose-finding research grant from the NIH/NIA, indicating a commitment to advancing its research and development efforts.

Neuronasal's technology is particularly relevant in the context of mTBI, where current treatment options are limited and many patients experience persistent symptoms. The company has established a pharmacologic proof-of-principle for its intranasal delivery system, which aims to mitigate the effects of reactive oxygen species (ROS) and inflammation that contribute to brain injury. With a significant market opportunity estimated at over $4 billion in the US and EU, Neuronasal is collaborating with notable institutions, including the Burke Neurological Institute and Weill Cornell Medical School, to further its research and clinical trials. The company is also pursuing additional patents related to its delivery methods and formulations, reinforcing its position in the field of neuroprotection and brain injury treatment.

United States

Neuronasal is a pharmaceutical company that specializes in a novel nose to brain drug delivery route for n-acetylcysteine (NAC) with patent protection and proven efficacy in delivering drugs to specific brain regions.

Neuronasal

Company Details